Health Condition 1: N771- Vaginitis, vulvitis and vulvovaginitis in diseases classified elsewhere
Conditions
Interventions
Intervention1: Itraconazole: Per oral Dose 200mg BD for 1 day
Control Intervention1: Fluconazole: Per oral Dose 150mg Stat on same day
Sponsors
Institute of Venereology Madras Medical College
Eligibility
Inclusion criteria
Inclusion criteria: 160 married women with vulvovaginal candidiasis attending the venereology OPD during the study period. Those who are giving consent to participate in the study. Those who are willing for follow up.
Exclusion criteria
Exclusion criteria: Pregnant women and women in the puerperal period. Patients with Chronic or Recurrent Vulvovaginal Candidiasis. Patients who have received systemic or topical antifungal treatment in the past 1 month. Patients with concurrent bacterial, viral or trichomonal vaginal infection. Patients with known allergy to azole drugs. Patients with coexistent Liver disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical effectiveness will be recorded as cure, improvement, failure and relapse as follows at Day 7: Cure: Complete disappearance of all signs and symptoms Improvement: Improvement or partial disappearance of signs and symptoms Failure: No change or worsening of signs and symptoms Relapse: Reappearance of signs and symptoms after documented cure had occurred. Timepoint: Day 7 | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical effectiveness will be recorded as cure, improvement, failure and relapse as follows: Cure: Complete disappearance of all signs and symptoms Improvement: Improvement or partial disappearance of signs and symptoms Failure: No change or worsening of signs and symptoms Relapse: Reappearance of signs and symptoms after documented cure had occurred. Timepoint: Day 21 | — |
Countries
India
Contacts
Public ContactDr S Kalaivani
Institute of Venereology, OP no. 119, Madras Medical College
Outcome results
None listed